Table 2.

Rates of MTX and TNFi persistence in patients with RA, PsA, and AS.

	n	Person-years	Median Persistence, yrs	HR (95% CI)	aHR (95% CI)
MTX
RA	26,708	23,773	1.13	Ref	Ref
PsA	2939	2477	0.94	1.12 (1.06–1.18)^*	1.10 (1.04–1.16)^*
AS	1880	1378	0.70	1.35 (1.28–1.44)^*	1.23 (1.16–1.31)^*
TNFi
RA	24,134	23,062	1.28	Ref	Ref
PsA	6705	6570	1.53	0.91 (0.87–0.95)^*	0.93 (0.89–0.97)^*
AS	3812	3460	1.15	1.06 (1.01–1.11)^*	1.00 (0.94–1.05)

↵* p < 0.05. Adjusted HR (aHR) from multivariable Cox models adjusted for age, sex, year, prescriptions for opioids, NSAID, MTX (TNF analyses only), sulfasalazine, hydroxychloroquine, leflunomide use in the past 3 months; diabetes, cancer, chronic kidney disease, asthma/chronic obstructive pulmonary disease, congestive heart failure, coronary artery disease, cerebrovascular disease, liver disease, obesity, depression, anxiety, bipolar disorder, chronic pain, peptic ulcer disease, Charlson score, hospitalizations in the past year, emergency room visits in the past year, no. outpatient visits, and psychiatric visits. TNFi models also adjusted for which TNFi patients received. MTX: methotrexate; TNFi: tumor necrosis factor inhibitor; RA: rheumatoid arthritis; PsA: psoriatic arthritis; AS: ankylosing spondylitis; NSAID: nonsteroidal antiinflammatory drugs.